Elsevier,
Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant (Ninth Edition), 2025, Pages 728-744.e4
This content aligns with Goal 3: Good Health. Public health programs at the governmental level are in need for prevention of the maternal-fetal transmission of these viruses and access to available antiviral therapies.
This study introduces an innovative method using DNA barcodes to accurately identify species, addressing the critical issue of trafficking invaluable medicinal plants like Trillium govanianum.
This study developed four deep learning models to identify potential Alzheimer's disease treatments from traditional Chinese medicine, specifically the Kaixinsan formula. The models successfully predicted compounds that showed significant anti-Alzheimer's activities in various experimental validations.
This article looks at complications that arise from combinations of Alzheimers and osteoporosis in mouse models
This article supports SDG 3 by showing that using an interactive mHealth application can reduce dementia risk factors in populations who are underserved and at increased risk.
Recent research on Alzheimer's disease (AD) suggests that microglia, immune cells in the brain, may play a beneficial role in early disease stages but become harmful in later stages due to various spatial, temporal, and transcriptional factors. Understanding the phenotypic heterogeneity and multiple states of microglia could lead to advancements in personalized medicine and improved treatment outcomes for AD patients.
This article summarizes current biomarkers, available treatments, and future therapeutic approaches for Alzheimer's disease, discussing drug targets like Amyloid β, Tau Protein, and various other mechanisms. Additionally, it highlights the historical use of Estradiol, outcomes of trials with antioxidants and omega-3 fatty acids, and ongoing clinical trials, providing a comprehensive overview of the evolving landscape in AD research and treatment.
This study identified key biochemical pathways and protein changes in the Alzheimer's disease (AD) human hippocampus, revealing increased expression of proteins VGF, GFAP, HSPB1, and APP, with UBC being most centrally involved, and highlighted the roles of four hub proteins (CD44, APP, ITGB2, APOE) linked to amyloid plaques and two (RPL24, RPS23) to neurofibrillary tangles, along with the impact of modified proteins on immune activation and synaptic disruption, uncovering potential therapeutic targets involving specific proteins, microRNAs, and transcription factors.
This study finds that impaired cellular immune dysfunction in AD patients was significantly correlated with abnormal MRS, and neuroimmune dysfunction may contribute to the pathogenesis of AD and alter the metabolism of neurotransmitters such as aspartic acid and MI in the brains of AD patients.
This study reveals that Dl-3-n-butylphthalide (NBP) improves learning deficits and reduces Aβ plaque deposition in Alzheimer's disease (AD) transgenic mice by enhancing microglial activation and phagocytosis of Aβ plaques. The therapeutic effects of NBP are linked to the AGE-RAGE signaling pathway, demonstrating its potential in alleviating cognitive impairment and neuroinflammation in AD.
